Clinical Trial

INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

Study acronym: INTERCEPT
Completed
View on ClinicalTrials.gov →
Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Protocol Amendment History 4 changes
critical Trial completed 2026-07-10
critical Primary endpoint(s) modified 2026-05-14
notable Primary completion pushed: 2026-03 -> 2026-05-22 2026-05-14
minor Completion pushed: 2026-03 -> 2026-05-22 2026-05-14
Trial Details
NCT Number NCT07417618
Lead Sponsor Brigham and Women's Hospital
Conditions Type 2 Diabetes, Overweight, ASCVD
Enrollment 60,000 participants
Start Date 2026-01-27
Primary Completion 2026-06-19 (estimated)
Study Completion 2026-06-19 (estimated)
Updated on ClinicalTrials.gov 2026-07-09